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Introduction {#sec1}
============

Parkinson\'s disease (PD) is a common neurodegenerative disorder characterized by progressive degeneration of dopamine (DA) neurons in the midbrain substantia nigra ([@bib36]). Fetal midbrain transplantation has been clinically performed in PD patients, and has resulted in therapeutic effects ([@bib31]). However, limited donor tissue, inconsistent therapeutic outcomes, and dyskinesia side effects ([@bib8], [@bib9]) prevented this approach from becoming a generalized therapeutic tool. These problems could be solved by culturing neural stem/precursor cells (NSCs) derived from dopaminergic ventral midbrain (VM) tissues, in which the quality and quantity of transplanted DA neurons could be systematically manipulated.

Midbrain-type DA (mDA) neurons are generated efficiently *in vitro* in NSCs cultured from the VM during early embryonic days, such as rat embryonic days 11--12 (E11--E12) ([@bib22], [@bib38]). DA neurogenic potential, however, declines severely during *in vitro* NSCs expansion ([@bib22], [@bib38], [@bib41]). In addition, expression of midbrain-specific markers FOXA2, LMX1A/B, and NURR1, critical for mDA neuron functions, survival, and phenotype maintenance ([@bib7], [@bib29]), is also lost during culturing VM-NSCs ([@bib29], [@bib33]). Additionally, NSCs expanded *in vitro* exhibit increased apoptotic cell death during or after differentiation, resulting in poor graft formation after transplantation ([@bib1], [@bib19], [@bib34], [@bib33]). Methods to halt these culture-dependent changes need to be developed to generate a systematic source of therapeutically competent donor cells for cell therapeutic approaches for PD.

Vitamin C (L-ascorbic acid; VC) is a crucial microconstituent in most tissues ([@bib26]). VC concentration is highest in the brain, and even higher during embryonic development ([@bib20]), suggesting specific VC roles during brain development. We and other groups have shown that VC promotes DA neuron differentiation by facilitating DA phenotype expression ([@bib12], [@bib22], [@bib41]), suggesting that VC treatment can be utilized in cell-based PD therapy. However, systematic analyses on the practical utility of using VC in PD cell therapy have not been attempted.

In this study, we show that VC treatment during VM-NSC expansion substantially rescues all the culture-dependent changes associated with the therapeutic capacity of donor NSCs in PD cell therapy. The effects of VC were achieved by inducing long-lasting epigenetic modifications to a set of mDA neuron developmental and phenotype genes.

Results {#sec2}
=======

VC Rescued Loss of DA Neurogenic Potential during *In Vitro* Expansion of VM-NSCs {#sec2.1}
---------------------------------------------------------------------------------

NSCs were isolated from naive rat embryo dopaminergic VMs at E12, and expanded in the presence of the mitogen basic fibroblast growth factor (bFGF) *in vitro*. Proliferating VM-NSCs were passaged every 4 days, and cells at each passage were induced to differentiate by withdrawing the mitogen ([Figure 1](#fig1){ref-type="fig"}A). The VM-NSCs expanded for a short period (4 days, unpassaged \[P0\]) and efficiently differentiated into DA neurons expressing tyrosine hydroxylase (TH), the key enzyme for DA biosynthesis; however, DA neuron differentiation was steeply decreased by longer expansion with increased cell passages ([Figures 1](#fig1){ref-type="fig"}B--1E). Altered cellular characteristics, including decreased differentiation potential during *in vitro* expansion, are commonly observed in stem/precursor cell cultures derived from mammalian tissues, regardless of tissue origin. This may be regarded as a phenomenon associated with cellular aging, given that similar changes in stem cell properties are manifest during *in vivo* aging ([@bib2], [@bib18]). As reactive oxygen species (ROS) are a major cause of cellular aging and senescence, we tested whether elimination of ROS by anti-oxidant treatment in VM-NSC cultures could rescue the culture-dependent loss of DA neurogenic potential. To this end, the anti-oxidants VC, vitamin E, reduced glutathione, or N-acetylcysteine were used as supplements during *in vitro* VM-NSC expansion, and subsequent culture differentiation was induced without the anti-oxidants ([Figure 1](#fig1){ref-type="fig"}A). ROS scavenging effects of all the anti-oxidants tested were confirmed by 2′,7′-dichlorofluorescin staining ([Figure S1](#mmc1){ref-type="supplementary-material"}A). However, among the tested anti-oxidants, only treatment with VC resulted in the prevention of DA neuron loss in passaged cultures ([Figures 1](#fig1){ref-type="fig"}F--1K), indicating that VC-specific actions, rather than general anti-oxidant effects, were responsible for the observed VC effect. VC treatment during NSC expansion was dramatic in cultures up to passage 1 (P1), which yielded P1 cultures, in which the TH^+^ cell yields (10.85% ± 1.2% of total DAPI^+^ cells) were as great as those achieved in untreated cultures at P0 (12.5% ± 0.35%) ([Figure 1](#fig1){ref-type="fig"}E). Virtually all the TH^+^ cells differentiated from VC-treated VM-NSCs at P1 expressed the other DA phenotypes (VMAT2, AADC, and DAT) ([Figures 1](#fig1){ref-type="fig"}L--1N) along with increases of their gene expression ([Figure 1](#fig1){ref-type="fig"}O), suggesting that VC treatment not only induced TH expression but exerted an effect on authentic DA neuron differentiation.Figure 1Vitamin C Treatment during VM-NSC Proliferation Rescued the Loss of DA Neurogenic Potential during *In Vitro* Expansion(A) Schematic of the experimental design.(B--D) Decline of DA neurogenic potential during *in vitro* cell expansion with serial passages in control VM-NSC cultures (without anti-oxidant treatment). Shown are representative images for TH^+^ DA neurons at differentiation day 6 (d6) in unpassaged cultures (P0, B), and cultures passaged one (P1, C) and two (P2, D) times.(E) DA neuronal yields (percent TH^+^ cells of total DAPI^+^ cells) are depicted as blue bars (control) and red bars (VM-NSCs expanded with VC \[200 μM\] during P0--P2).(F--K) DA neuronal yields of the NSC cultures expanded for 8 days (up to P1) in the presence or absence of various anti-oxidant treatments. Shown are representative images of TH^+^ DA neurons (F--J) and a quantitative graph (K). Values represent the mean ± SEM; n = 3 independent experiments at ^∗^p \< 0.05 or ^∗∗^p \< 0.01, Student\'s t test (E) and one-way ANOVA with Tukey\'s post hoc analysis (K). Scale bar, 50 μm.(L--O) VM-NSCs expanded with VC treatment yield TH^+^ DA neurons equipped with other DA neuron phenotypic markers. P1 cultures expanded with VC were differentiated in the absence of VC for 12 days and subjected to co-immunostaining with DAT (L), AADC (M), and VMAT2 (N). Along with an increase in *Th* mRNA expression, expression of other DA phenotype markers at d12 increased upon VC treatment during the expansion period (O). ^∗^p \< 0.01, n = 3 independent experiments, Student\'s t test. Scale bar, 50 μm.

The dramatic effect of VC treatment was not sustained in cultures that had undergone one additional passage (at P2), in which TH^+^ DA neuronal yields from VC-treated NSCs were also sharply reduced to 1.22% ± 0.1%; this was, however, still significantly greater than the VC-untreated control (0.44% ± 0.22%; p \< 0.05, n = 3 independent experiments) ([Figure 1](#fig1){ref-type="fig"}E). Based on these findings, the following experiments were carried out to evaluate the effect of VC using P1 cultures, unless otherwise noted.

Midbrain-Specific Marker Expression, Presynaptic Function, and Toxic Resistance of mDA Neurons Differentiated from VC-Treated VM-NSCs {#sec2.2}
-------------------------------------------------------------------------------------------------------------------------------------

The effect of VC on DA neuron differentiation has been reported in previous studies ([@bib12], [@bib22], [@bib41]). However, in addition to DA neuron yield, successful cell therapeutic outcome relies on the expression of midbrain phenotypes, neuronal maturation, presynaptic functions, and cell survival of the differentiated DA neurons. To investigate VC effects on those aspects, we applied VC during VM-NSC proliferation followed by VC withdrawal during differentiation. The rationale for the VC withdrawal during differentiation is to closely mimic the cell transplantation condition, whereby VC addition is limited to the donor cell preparation period (before cell transplantation), since the proliferating NSC stage is regarded as the most appropriate stage for cell transplantation, given that extensive cell death is associated with transplanting differentiating/differentiated neurons ([@bib39]).

mDA neurons are characterized by the continued expression of midbrain-specific developmental factors, such as FOXA2, LMX1A, and NURR1, after termination of development in the adult midbrain. Midbrain factor expression in mDA neurons is critical for their survival and function ([@bib7], [@bib29]), but disappears in aged or PD midbrains ([@bib29]). A similar loss of midbrain marker expression is also seen in mDA neurons maintained in culture for long periods of time or after transplantation ([@bib33]), indicating that it is the prime problem to be solved to permit successful PD cell-based therapy ([@bib21]). Untreated control cultures at P1 yielded TH^+^ DA neurons, only portions of which expressed the midbrain markers NURR1 (62%), FOXA2 (73%), and LMX1A (63%) at differentiation day 6 (d6) ([Figures 2](#fig2){ref-type="fig"}A--2C). Interestingly, in addition to enhanced DA neuronal yields, almost all TH^+^ DA neurons differentiated from VC-treated NSCs expressed midbrain markers (93% \[NURR1\], 98% \[FOXA2\], and 91% \[LMX1A\]).Figure 2VM-NSCs Expanded with VC Yield DA Neurons with Enhanced Midbrain-Specific Marker Expression, Presynaptic Neuronal Maturation, Cell Survival, and Resistance against Toxic InsultsVM-NSCs were *in vitro* expanded with or without (control) VC up to P1, and then differentiated in the absence of VC for 6--15 days.(A--C) Co-expression of midbrain-specific markers in differentiated DA neurons. Graphs on the right depict the percentage of TH^+^ cells co-expressing the midbrain-specific markers NURR1 (A), FOXA2 (B), and LMX1A (C) out of the total number of TH^+^ cells at d6. ^∗^p \< 0.001, n = 30 microscopic fields, Student\'s t test. White arrows indicate TH^+^ DA neurons co-expressing the midbrain markers.(D--F) Morphological, synaptic, and functional maturity of DA neurons estimated by TH^+^ fiber length per DA neuron at d15, n = 60 cells (D), number of synapsin^+^ puncta along the TH^+^ neurites (100 μm; n = 20 neurites) (E), and presynaptic DA release, n = 3 independent experiments (F). Medium (48 hr), DA levels in the media conditioned in the differentiated cultures for 48 hr (d13--15); KCl evoked (30 min), DA levels evoked by KCl-mediated depolarization for 30 min. n = 3 independent experiments. ^∗^p \< 0.001, Student\'s t test.(G--J) Effect of VC pretreatment during VM-NSC expansion on differentiated cell survival/death and resistance against toxins. VM-NSCs expanded with or without VC were differentiated for 8 days without VC. General cell death (G) and DNA damage (H) were estimated by the percentage of cells positive for EthD1^+^ and the percentage of cells with \>3 γH2AX foci at d8, respectively. The differentiated cultures at d8 were exposed to H~2~O~2~ or 6-OHDA (500 μM and 1,000 μM) for 8 hr and viable TH^+^ DA neurons were counted on the following day (I and J). ^∗^p \< 0.05 or ^∗∗^p \< 0.01, n = 3 independent experiments, Student\'s t test.Scale bars, 50 μm.

In morphometric assessments, total fiber lengths per TH^+^ DA neuron were significantly greater in cultures differentiated from VM-NSCs expanded with VC supplementation, compared with untreated control cultures (164 μm versus 134 μm, [Figure 2](#fig2){ref-type="fig"}D). The synaptic vesicle-specific markers synapsin^+^ puncta were more abundantly localized in TH^+^ DA neuron neurites differentiated from VC-treated NSCs ([Figure 2](#fig2){ref-type="fig"}E). We further observed that presynaptic DA release ([Figure 2](#fig2){ref-type="fig"}F) was greater in cultures differentiated from VC-treated NSCs. Taken together, these findings indicate that maturity of DA neurons was morphologically, synaptically, and functionally enhanced by VC pretreatment.

A portion of cells undergo cell death during differentiation. Increased cell death during NSC differentiation is another characteristic of cultured NSCs that have undergone longer periods of cell expansion (data not shown and [@bib33]). Cell death during/after differentiation was greatly reduced in cultures expanded with VC supplementation, as estimated by ethidium homodimer 1 (EthD-1) positivity at d8 ([Figure 2](#fig2){ref-type="fig"}G). In addition, γH2AX foci, a DNA damage indicator observed during PD progression, were greatly reduced in VC pretreated differentiated cultures ([Figure 2](#fig2){ref-type="fig"}H). Remarkably lower proportions of DA neurons died after exposure to toxic stimuli induced by H~2~O~2~ or 6-hydroxydopamine (6-OHDA) in cultures differentiated from NSCs pretreated with VC ([Figures 2](#fig2){ref-type="fig"}I and 2J). In addition, TH^+^ cells that survived toxin treatment in VC pretreated cultures displayed a healthy neuronal shape with extensive neurite outgrowth, while most of the surviving TH^+^ cells in the control cultures had blunted or fragmented neurites (insets of [Figures 2](#fig2){ref-type="fig"}I and 2J), a neuronal aging and degenerative phenotype ([@bib13]). We emphasize again that all the effects observed in the differentiated cultures were not directly mediated by VC, as the differentiated cells were cultured in the absence of VC.

VC-Mediated Epigenetic Control within a Range of mDA Neuron Developmental and Phenotype Genes {#sec2.3}
---------------------------------------------------------------------------------------------

In view of VC\'s anti-oxidant action, mDA neuron differentiation enhanced by VC treatment could be attained by a selective mechanism, in which VC enhanced cell survival and proliferation selectively in DA neuronal lineage cells. However, NSC cultures derived from early rat embryonic brains are highly and sufficiently proliferative and viable in the presence of the mitogen bFGF. Thus, none of the anti-oxidant treatments tested, including VC, significantly altered VM-NSC survival and proliferation up to P1 (the stage during which all analyses in this study were done) ([Figures S1](#mmc1){ref-type="supplementary-material"}B and S1C), ruling out the possibility of a selective mechanism in VC-mediated DA neuron differentiation.

Without expression changes of general NSC-specific (Nestin, SOX2) and anterior brain region-specific (OTX2) markers ([Figures S2](#mmc1){ref-type="supplementary-material"}A--S2C), VC treatment during VM-NSC expansion enhanced the percentage of cells expressing the VM-specific NSC markers FOXA2 and LMX1A at d0 (before differentiation induction) ([Figure 3](#fig3){ref-type="fig"}A). FOXA2 and LMX1A are expressed in dopaminergic NSCs from early developing VMs and act as the master regulators for mDA neuron development by inducing expression of a battery of later developmental genes, such as NURR1, PITX3, and Neurogenin2 (Ngn2) ([@bib5], [@bib27], [@bib42]). In addition, as mentioned earlier, expression of FOXA2 and LMX1A that continued in adult mDA neurons was critical for survival, phenotype maintenance, and functions of this neuronal type. Of note, the percentage of FOXA2^+^ and LMX1A^+^ cells increased by VC treatment during the NSC stage was sustained after differentiation (after VC withdrawal) ([Figure 3](#fig3){ref-type="fig"}A, graph); this was directly associated with increased FOXA2/LMX1A expression in differentiated DA neurons ([Figures 2](#fig2){ref-type="fig"}B and 2C) and, thus, enhanced DA neuron survival and presynaptic function ([Figures 2](#fig2){ref-type="fig"}F--2J).Figure 3VC Treatment Promoted Expression of FOXA2 and LMX1A in VM-NSCs along with TET1- and Jmjd-Mediated Changes in Global 5hmC/5mC and H3K27m3/H3K9m3 Levels(A and B) FOXA2 and LMX1A expression in undifferentiated and differentiated VM-NSC cultures estimated by the percentage of immunoreactive cells among total DAPI^+^ cells at d0 and d6 (A) and real-time PCR at d0 (B).(C) TET enzyme activity in the nuclear fraction at d0.(D--G) Global 5hmC (D and E) and 5mC (F and G) levels estimated by DNA dot blot (D and F) and immunocytochemical (E and G) analyses at d0.(H) JMJD3 enzyme activity.(I--K) VC effects on global H3K27m3 and H3K9m3 levels estimated by western-blot (I) and immunocytochemical (J and K) analyses at d0. Intensities of the bands in (I) were quantified using ImageJ software, and the values normalized to histone 3 (H3) are depicted in the graph on the right.Values represent the mean ± SEM; n = 3 independent experiments at ^∗^p \< 0.05 or ^∗∗^p \< 0.01, Student\'s t test. Scale bars, 50 μm.

Next, we sought to determine how VC promoted FOXA2 and LMX1A expression in proliferating VM-NSCs. VC treatment enhanced the mRNA levels of *Foxa2* and *Lmx1a* ([Figure 3](#fig3){ref-type="fig"}B), indicating that VC acted at the gene transcription level. In addition to its anti-oxidant role, VC acts as a cofactor for the family of Fe(II)-2-oxoglutarate-dependent dioxygenases ([@bib24]), including epigenetic control enzymes such as ten-eleven-translocation 1--3 (TET1--3) and Jumonji C (JmjC)-domain-containing histone demethylases (JMJDs) ([@bib12]). VC treatment of proliferating VM-NSCs greatly enhanced TET enzyme activity in nuclear fractions ([Figure 3](#fig3){ref-type="fig"}C), with which methylated cytosine on CpG sites (5-methylcytosine \[5mC\]) of DNA is hydroxylated into 5-hydoxymethylcytosine (5hmC). Consequently, global 5hmC levels estimated by immunoblotting ([Figure 3](#fig3){ref-type="fig"}D) and immunocytochemical ([Figure 3](#fig3){ref-type="fig"}E) analyses were greatly increased in VC-treated VM-NSCs; this was accompanied by a significant decrease in global 5mC levels ([Figures 3](#fig3){ref-type="fig"}F and 3G). The increase in JMJD enzyme activity was observed in the nuclear fractions of VC-treated VM-NSCs ([Figure 3](#fig3){ref-type="fig"}H). Among the histone methylations tested, global levels of H3K27m3 and H3K9m3 were reduced by VC treatment ([Figures 3](#fig3){ref-type="fig"}I--3K).

Based on these findings, we assessed 5hmC/5mC and H3K27m3/H3K9m3 levels in the promoter regions of *Foxa2* and *Lmx1a* ([Figures 4](#fig4){ref-type="fig"}A and 4D). Hydroxymethylated DNA immunoprecipitation qPCR (hMeDIP-qPCR) and MeDIP-qPCR analyses revealed that in the *Foxa2* promoter regions 5hmC was more abundant in VC-treated NSCs, while 5mC levels were reduced ([Figure 4](#fig4){ref-type="fig"}B). We further observed a decrease in H3K27m3 and H3K9m3 levels in the *Foxa2* promoter regions after VC treatment ([Figure 4](#fig4){ref-type="fig"}C). Similar VC-mediated epigenetic changes were also observed in a CpG-abundant region of the *Lmx1a* gene promoter ([Figures 4](#fig4){ref-type="fig"}E and 4F). Notably, recruitment of TET1, JMJD3, and JMJD2 proteins to the *Foxa2* and *Lmx1a* promoter regions in VM-NSCs was dramatically increased by VC treatment ([Figures 4](#fig4){ref-type="fig"}G and 4H), indicating that the epigenetic enzyme abundance in the promoters, along with their enzyme activity increases, contributed to the observed VC-induced epigenetic changes at the promoter regions. In the developing brain, intracellular VC contents are much higher than in extracellular fluids due to the action of sodium-dependent VC transporter 2 (SVCT2) transporting VC into the intracellular space against its gradient in a sodium- and pH-dependent manner ([@bib40]). Blocking SVCT2 action by lowering pH or by treatment with quercetin, a specific SVCT2 inhibitor ([@bib10], [@bib23]), abolished the VC-mediated changes to 5mC/5hmC and H3K27m3/H3K9m3 on the *Foxa2* and *Lmx1a* genes ([Figures 4](#fig4){ref-type="fig"}I and 4J). These findings collectively demonstrated the direct action of VC on observed epigenetic changes. As DNA hydroxymethylation/demethylation and histone demethylation are associated with open DNA/chromatin structures, the VC-induced epigenetic changes in the *Foxa2* and *Lmx1a* promoters were responsible for the observed gene expression increases. In addition, considering the actions of FOXA2 and LMX1A as the master regulators of mDA neuron development, the VC-mediated epigenetic controls in those master genes are proposed to be the central mechanism for the effects of VC on enhanced mDA neuron differentiation. Interestingly, the VC-mediated changes in 5mC/5hmC and H3K27m3/H3K9m3 in *Foxa2* and *Lmx1a* were maintained in the differentiated cells long after VC withdrawal ([Figures 4](#fig4){ref-type="fig"}B, 4C, 4E, and 4F). The sustained open DNA/chromatin structures of these genes likely contributed to sustained FOXA2 and LMX1A expression in DA neurons in differentiated cultures, as shown in [Figures 2](#fig2){ref-type="fig"}B and 2C.Figure 4VC-Induced Epigenetic Changes on *Foxa2* and *Lmx1a* Promoters(A and D) Schematics for the rat *Foxa2* (A) and *Lmx1a* (D) promoters with CpG-enriched regions (indicated by box) targeted for the DIP- and ChIP-PCR analyses. In the *Lmx1a* promoter, the CpG region predicted to be a consensus FOXA2 binding (FB) site was analyzed.(B, C, E, and F) Levels of 5hmC/5mC and H3K27m3/H3K9m3 in the promoter regions of *Foxa2* (B and C) and *Lmx1a* (E and F) in undifferentiated (d0) and differentiated (d6) VM-NSC cultures. Data are presented as log~2~ values of the fold changes (VC^+^/VC^−^). N/A, not amplified.(G and H) TET1, JMJD3, and JMJD2 protein recruitments to the *Foxa2* (G) and *Lmx1a* promoters (H) at d0.(I and J) The VC-induced epigenetic changes on the *Foxa2* (I) and *Lmx1a* (J) promoters was abolished by blocking SVCT activity by lowering pH (pH 5) and with treatment by the SVCT2 inhibitor, quercetin (10 μM). The inhibitors and vehicle (−) were treated for 3 hr prior to VC treatment. The levels of the epigenetic proteins and codes were determined in regions.Significance at ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, n = 3 independent experiments, t test.

It has been reported that open epigenetic signatures on late developmental/differentiated phenotype genes are frequently established during an early stage of stem cell differentiation, without their actual expression ([@bib25]). Thus, we further examined the effect of VC on epigenetic changes in later mDA developmental and differentiated genes. NURR1, the transcription factor critical for DA phenotype gene expression, begins to be expressed from late mDA neuron progenitor cells ([@bib35], [@bib44]). Consistent with this, NURR1-expressing cells were not detected in proliferating VM-NSC stages (d0), but began to be detected from d2 ([Figures 5](#fig5){ref-type="fig"}A and 5B). The percentage of NURR1^+^ cells at d2 was greater in cultures treated with VC during the proliferating NSC stage, and this increase in NURR1 expression was sustained during the later differentiation period ([Figures 5](#fig5){ref-type="fig"}A and 5B). Interestingly, compared with untreated controls, increased 5hmC levels with 5mC decreases and the decrease of H3K27m3/H3K9m3 at *Nurr1* promoter regions (consensus FOXA2 binding sites, [Figure 5](#fig5){ref-type="fig"}C) were observed in the VC-treated cultures from the undifferentiated stage (d0) ([Figures 5](#fig5){ref-type="fig"}D and 5E) when no NURR1 expression was detected ([Figure 5](#fig5){ref-type="fig"}A, graph). These epigenetic code changes became greater at d2 and were maintained at least up to d6. Along with the activated epigenetic patterns associated with open DNA/chromatin structures, FOXA2, a transcription factor known to directly induce NURR1 transcription ([@bib42]), was more abundantly recruited to the *Nurr1* promoter regions at d2 in the culture pretreated with VC ([Figure 5](#fig5){ref-type="fig"}F). Consequently, the percentage of FOXA2^+^ cells co-expressing NURR1 at d2 was significantly greater in cultures pretreated with VC ([Figure 5](#fig5){ref-type="fig"}G).Figure 5VC-Induced Epigenetic Changes in Later Developmental and Differentiated mDA Neuronal GenesUndifferentiated VM-NSCs proliferated in the presence (VC^+^) or absence of VC (VC^−^), then differentiation without VC for 6 days.(A and B) Expression of the later mDA developmental gene *Nurr1* assessed by immunocytochemical (A) and real-time qPCR (B) analyses. ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, n = 3 independent experiments, Student\'s t test. Scale bar, 50 μm.(C--G) Effects of VC pretreatment on the levels of 5hmC/5mC and H3K27m3/H3K9m3 on the *Nurr1* promoter. (C) Schematic for the rat *Nurr1* promoter with consensus FOXA2 binding sites (FB) targeted for the DIP- and ChIP-PCR analyses. The hMeDIP/MeDIP-qPCR for 5hmC/5mC (D) and ChIP-qPCR analyses for H3K27m3/H3K9m3 (E) were carried out over the differentiation period (d0--d6). (F and G) Along with increases of FOXA2 protein recruitment to the *Nurr1* promoter at d2, n = 3 independent experiments (F), the percentage of FOXA2^+^,NURR1^+^ cells among total NURR1^+^ cells, n = 3 independent experiments (G) was greater in cultures differentiated from VC-treated NSCs. ^∗^p\<0.05; ^∗∗^p\<0.01; ^∗∗∗^p\<0.001, t-test.(H--J) Effects of VC pretreatment on the levels of 5hmC/5mC and H3K27m3/H3K9m3 in the *Th* gene promoter regions. DIP- and ChIP-PCR analyses were performed to assess epigenetic code changes in consensus NURR1 binding (NB) and 10 CpG sites of the rat *Th* promoter over the differentiation period (d0--d6). ^∗^p \< 0.05, ^∗∗^p \< 0.01, n = 3 independent experiments, Student\'s t test.(K) NURR1 protein recruitment to the *Th* promoter regions at d6, n = 3 independent experiments. ^∗^p \< 0.05, Student\'s t test.(L) NURR1 efficiency in inducing TH expression estimated by the percentage of NURR1^+^,TH^+^ cells among total NURR1^+^ cells at d6. ^∗^p \< 0.05, n = 3 independent experiments, Student\'s t test.

VC treatment during the proliferation period also induced similar epigenetic changes (except 5hmC/5mC at d0) on the *Th* promoter ([Figure 5](#fig5){ref-type="fig"}H), a DA phenotype gene expressed in terminally differentiated DA neurons, from d0 ([Figures 5](#fig5){ref-type="fig"}I and 5J). There was an increasing trend in the activated epigenetic code levels, especially in 5hmC at *Th* promoters, during the 6 days of differentiation. Consistent with this, chromatin immunoprecipitation (ChIP)-qPCR analyses showed significantly greater NURR1 protein abundance at the consensus NURR1 binding sites and a CpG-enriched site (close to the transcription start site) of the *Th* promoter at d6 in VC-pretreated cultures ([Figure 5](#fig5){ref-type="fig"}K), resulting in an enhanced ability of NURR1 to induce TH expression (percent NURR1^+^,TH^+^ of total NURR1^+^ cells) upon VC pretreatment ([Figure 5](#fig5){ref-type="fig"}L). Again, the VC-induced epigenetic changes to the *Nurr1* and *Th* gene promoters were abolished by blocking SVCT2 activity ([Figure S3](#mmc1){ref-type="supplementary-material"}). VC administration to proliferating VM-NSCs did not affect the epigenetic codes on the other neuronal subtype genes such as tryptophan hydroxylase 2 (*Tph2*, serotonergic neurons) and glutamic acid decarboxylase 67 (*GAD67*, GABAergic) ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B) along with no significant alteration in their mRNA expression levels ([Figure S4](#mmc1){ref-type="supplementary-material"}D). By contrast, VC-mediated changes to 5hmC/5mC and H3K27m3/H3K9m3 levels observed in the *Th* promoter were similarly detected in the promoter of glial fibrillary acidic protein (*Gfap*), specific for astrocytes (consensus STAT binding region) ([Figure S4](#mmc1){ref-type="supplementary-material"}C). Consistently, mRNA expression of *Gfap* as well as GFAP^+^ astrocyte yields were significantly enhanced by VC pretreatment ([Figures S5](#mmc1){ref-type="supplementary-material"}D and S5E). In summary, we showed that VC treatment of proliferating VM-NSCs induced epigenetic changes into open DNA/chromatin structures in a range of DA neuron developmental genes specific to early (*Foxa2*, *Lmx1a*) and intermediate (*Nurr1*) mDA neuron progenitors and terminally differentiated DA neurons (*Th*). The VC-mediated epigenetic changes in these genes were sustained long after VC withdrawal, including in terminally differentiated mDA neurons. Thus, sustained epigenetic changes resulting from transient VC treatment of proliferating VM-NSCs were responsible for enhanced DA neuron differentiation and sustained midbrain-specific factor expression in differentiated mDA neuronal cells.

Cell Transplantation in PD Rats {#sec2.4}
-------------------------------

Based on the *in vitro* findings, we ultimately assessed the therapeutic functions of VM-NSCs expanded with VC supplementation in a PD animal model. For this experiment, rat E12 VM-NSCs were expanded *in vitro* for 8 days (passaged at day 4 of proliferation) in the presence or absence of VC (P1 d0), harvested, and intrastriatally transplanted into a hemi-parkinsonian rat model. While functional recovery of PD rats has been demonstrated using transplantation of short-term expanded NSCs derived from early embryonic VM tissues ([@bib16], [@bib17], [@bib38], [@bib39]), this would not be expected to be achieved by transplanting NSCs expanded and passaged for a longer period due to the loss of DA neurogenic potentials ([@bib16], [@bib22], [@bib39], [@bib41]), loss of midbrain-specific factor expression, and poor cell survival during and after differentiation ([@bib1], [@bib19], [@bib34]). As expected, an amphetamine-induced rotation test revealed no significant reduction in rotation scores compared with pretransplantation values in PD rats grafted with control NSCs (n = 7). In contrast, dramatic behavioral recoveries were achieved in animals grafted with VM-NSCs expanded in the presence of VC. In all eight rats grafted with VC-pretreated NSCs, without exception, rotations were reduced at 8 weeks post transplantation ([Figures 6](#fig6){ref-type="fig"}A--6C). In the stepping test ([Figure 6](#fig6){ref-type="fig"}D), rats grafted with VC-pretreated NSCs used their lesioned (left) forelimbs more often than did rats grafted with control NSCs. The percentage of adjusting steps of the lesion-containing paw was 37.3% ± 3.9% (VC) versus 9.7% ± 2.2% (control) of the right unlesioned paw, n = 7 (control) and n = 8 (VC), p = 7.3 × 10^−8^, ANOVA followed by Tukey\'s post hoc analysis.Figure 6VC-Treated NSC Transplantation into Parkinson\'s Disease Rat ModelNSCs derived from rat embryonic VM at E12 were expanded *in vitro* with or without VC for 8 days. The donor cells were harvested (equivalent to P2 culture), and intrastriatally transplanted into 6-OHDA-lesioned PD model rats. Behavioral (A--D) and histological (E--S) analyses were carried out during or at 8 weeks post transplantation.(A--D) Amphetamine-induced rotation scores. The ipsilateral net rotation values of individual animals transplanted with control NSCs (A) and VC-NSCs (B) and their mean ± SEM (C) are depicted. n = 8 rats (VC-NSC), n = 7 rats (control NSC). Significant differences from the control at each post-transplantation time point at ^∗^p \< 0.05 and ^∗∗^p \< 0.01, two-way ANOVA. Behaviors of the transplanted animals were further assessed by Stepping test (D) at 8 weeks post transplantation: ^∗^p \< 0.001, ANOVA followed by Tukey\'s post hoc analysis.(E--S) Histological analyses 8 weeks post transplantation. (E--G) Graft volume (E), total number of TH^+^ cells in graft per animal (F), and TH^+^ cell density in graft (G). ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, t test. (H and I) Overviews of TH^+^ cell grafts. Insets show TH^+^ DA neuron morphology in grafts shown at high magnification. (J--R) Co-expression of mature neuronal (HuC/D and NeuN) (N--Q), midbrain-specific (FOXA2 and NURR1) (J--M), and A9 nigral mDA neuronal (GIRK2) (R) markers in TH^+^ DA cells at 8 weeks post transplantation. (S) DARPP-32^+^ striatal neurons adjacent to TH^+^ cells in the VC-NSC graft.Scale bars, 500 μm (H and I) and 30 μm (J--S).

Consistent with the observed increased survival of differentiating/differentiated cells from VC-pretreated NSCs *in vitro* ([Figures 2](#fig2){ref-type="fig"}G--2J), histological analyses performed 8 weeks post transplantation exhibited much larger graft formation in rats transplanted with VC-treated NSCs than control NSCs (0.95 ± 0.11 mm^3^ in VC group, n = 8 versus 0.13 ± 0.04 in the control group, n = 7, p = 1.4 × 10^−4^, Student\'s t test, [Figures 6](#fig6){ref-type="fig"}E, 6G, 6H, and 6I). Consistently, more abundant cleaved caspase-3^+^ apoptotic cells in grafts were detected in the control group compared with the VC group ([Figure S5](#mmc1){ref-type="supplementary-material"}A). None in the control and VC-treated NSC grafts were positive for the proliferating cell markers of proliferating cell nuclear antigen and phospho-histone H3 ([Figures S5](#mmc1){ref-type="supplementary-material"}B and S5C). There were 1,802 ± 338 TH^+^ cells (VC) versus 260 ± 78 TH^+^ cells (control) in the graft per animal ([Figure 6](#fig6){ref-type="fig"}F). However, the cell densities of general neuronal (HuC/D^+^, [Figure S5](#mmc1){ref-type="supplementary-material"}D) and serotonergic neuronal cells (5-hydroxytryptamine; 5-HT^+^, [Figure S5](#mmc1){ref-type="supplementary-material"}E) were not significantly different between the control and VC grafts. Consistent with the observed *in vitro* VC effects on astrocytic differentiation ([Figures S4](#mmc1){ref-type="supplementary-material"}D and S4E), GFAP^+^ astrocytes were greater in the grafts generated by VC-treated NSCs ([Figure S5](#mmc1){ref-type="supplementary-material"}F). TH^+^ cells in the VC-treated NSC grafts exhibited more mature neuronal shapes than those in the control grafts ([Figures 6](#fig6){ref-type="fig"}H and 6I, insets). In addition, there was a very clear difference in the co-expression of markers specific for mature mDA neurons in TH^+^ cells, whereby in the control grafts virtually none or a few of the TH^+^ cells were positive for mature neuronal and mDA neuronal markers ([Figures 6](#fig6){ref-type="fig"}J, 6L, 6N, and 6P). These findings are consistent with lack of mature neuron formation from grafted NSCs ([@bib30], [@bib43]) and the loss of NURR1 and FOXA2 expression in stressful environments ([@bib29]). In clear contrast, expression of mature neuronal (NeuN and HuC/D) and mDA neuronal (FOXA2, NURR1, and GIRK2) markers was faithfully co-localized in virtually all TH^+^ cells in the grafts generated by VC-treated NSC transplantation ([Figures 6](#fig6){ref-type="fig"}K, 6M, 6O, 6Q, and 6R). The TH^+^ mDA neurons in the graft were neighbored by cells positive for dopamine and cyclic AMP-regulated phosphoprotein 32 (DARPP-32), a marker for striatal postsynaptic neurons receiving signal from nigral mDA neurons ([Figure 6](#fig6){ref-type="fig"}S). These findings collectively suggest that VC treatment during VM-NSC expansion yielded therapeutically competent donor cells for use in cell therapeutic approaches to treating PD.

Discussion {#sec3}
==========

The most serious drawback associated with utilizing tissue-specific stem cell cultures in research and therapies is that their original properties and functionalities are altered during *in vitro* culturing. Cultured cells are expected to be exposed to cellular stresses during *in vitro* cell expansion and passaging. Since ROS is a major molecule causing loss of cell functionality associated with injury and aging, we tested whether scavenging ROS by anti-oxidant treatment could rescue the loss of DA neurogenic potential that occurs during culture of VM-NSCs. Our data showed that none of the anti-oxidants tested, except VC, prevented this culture-dependent change. In addition, inhibition of cell senescence by treatment with SB202190 (a P38-MAPK inhibitor) had no rescuing effect (data not shown), suggesting that ROS or cellular aging/senescence was not the mechanism responsible for the loss of DA neuron yield in cultured VM-NSCs. By contrast, cellular aging/senescence is a leading molecular mechanism causing loss of functionality in stem cells present in adult tissues (reviewed in [@bib37]), and anti-senescence reagents could prevent culture-dependent changes in stem cell cultures derived from adult tissues ([@bib6]). As DA neuron formation occurred in VM tissues at an early embryonic stage, our cultures were derived from embryonic VMs. Based on these findings, it was likely that cellular aging/senescence was not the critical factor responsible for the functionality changes in cultured stem cells derived from embryonic tissues, although it was the major mechanism for loss of stem cell functions derived from adult tissues. Instead, the culture-dependent changes of the NSCs derived from embryonic tissues were likely to be associated with the developmental program, in which DA neurogenic potential was physiologically lost in late NSCs that underwent several additional rounds of cell cycling in the developing VM as development proceeded.

The expression of midbrain factors FOXA2 and NURR1 is critical for mDA neuron survival, function, and phenotype maintenance ([@bib7], [@bib29]). However, expression of these factors disappears in aged and toxic environments ([@bib29]). Similarly, grafted mDA neurons easily undergo loss of midbrain factor expression in hostile brain environments ([Figure 6](#fig6){ref-type="fig"} and [@bib33]). Therefore, expression of midbrain-specific factors in grafted mDA neurons is critical for the success of cell therapy for PD ([@bib21]). In addition to increased DA neuronal yield, VC pretreatment of donor NSCs maintained midbrain marker expression in grafted mDA neurons long after transplantation, which was closely related to enhanced grafted cell survival and functions, and ultimately enhanced therapeutic outcomes. Another characteristic of NSCs altered during *in vitro* expansion as well as *in vivo* brain development is transition of NSC differentiation propensity from neuronal to astrocytic differentiation ([Figures S4](#mmc1){ref-type="supplementary-material"}D and S4E; [@bib1], [@bib2], [@bib3], [@bib32]). Based on the observed effect of VC in preventing culture-dependent changes, it was expected that VC could also prevent neuron-to-astrocyte transition during *in vitro* culturing. However, contrary to our expectations, VC treatment rather strongly enhanced astrocytic differentiation from cultured VM-NSCs via DNA/histone demethylation in the *Gfap* promoter region ([Figure S4](#mmc1){ref-type="supplementary-material"}C), indicating that VC-mediated effects on VM-NSC cultures are not completely associated with prevention of culture- or development-dependent processes. Based on the physiologic neurotrophic actions of brain astrocytes ([@bib14], [@bib28]), transplantation of astrocytes alone or together with neurogenic donor cells has become a therapeutic possibility for treating intractable brain disorders ([@bib4]). Thus, the VC effect on astrocyte differentiation is another beneficial contributor to attain improved therapeutic outcomes achieved by transplanting VC-treated NSCs, whereby astrocytes differentiated from the grafted NSCs exert trophic support for neuronal differentiation/maturation and survival in grafted brains. It was noted that TH^+^ DA neuronal cells in the grafts formed by VC-treated NSCs were more abundantly surrounded by GFAP^+^ astrocytes ([Figure S5](#mmc1){ref-type="supplementary-material"}F).

In this study, we demonstrated that VC exerted its observed effects via DNA/histone demethylation-based epigenetic control on DA neuron developmental genes. A similar epigenetic control mechanism was demonstrated in our previous study by treatment with VC during NSC differentiation ([@bib12]). However, epigenetic regulation and gene expression induced by VC treatment of differentiating NSCs was limited to terminally differentiated DA neuron genes such as *Th* and *Dat*. Thus, without effects on the expression of midbrain-specific factors and differentiated cell survival, the therapeutic value of the previous VC treatment method seems to be marginal. By contrast, the effect of VC treatment during NSC expansion covered changes in a wide range of mDA neuron developmental and phenotype genes, such as those acting at early undifferentiated stages of VM-NSCs (*Foxa2*, *Lmx1a*), intermediate mDA neuron progenitors (*Nurr1*), and terminally differentiated mDA neurons (*Th*). Interestingly, the epigenetic status of those genes was maintained in differentiated mDA neurons long after VC withdrawal. These findings suggest that transient VC treatment can induce a stable and long-lasting epigenetic change in mDA neuronal genes. It is also possible that VC treatment only triggers the mDA neuron developmental cascade by directly promoting the expression of FOXA2 and LMX1A, the master regulators expressed in undifferentiated VM-NSCs. Induction of the later developmental factor expressions subsequently follows in the facilitated developmental cascade. The later developmental factors may take over VC-mediated epigenetic regulatory actions and contribute to the maintenance of the epigenetic status during later differentiation stages. Consistent with this, the epigenetic opening roles of FOXA2, NURR1, and PITX3 on DA phenotype genes have previously been reported ([@bib15], [@bib42]). Regardless of the mechanism, the sustained open DNA/chromatin structures surely contributed to the generation of mDA neurons expressing midbrain-specific markers and promoted resistance to toxic stimuli both *in vitro* and *in vivo* long after transplantation.

For the application of VC treatment in the clinical setting of PD cell therapy, the VC effects observed in this study should be replicated in human NSC cultures. Thus, we treated proliferating NSCs derived from human embryonic stem cells (hESCs) ([@bib34]) with VC, and differentiation of the human NSCs was induced without VC. Similar to rodent VM-NSC cultures, VC pretreatment greatly promoted differentiating/differentiated cell survival in hESC-NSC cultures ([Figure S6](#mmc1){ref-type="supplementary-material"}A). In addition, TH^+^ DA neuronal yields were significantly enhanced in the cultures differentiated from the VC-pretreated human NSCs ([Figure S6](#mmc1){ref-type="supplementary-material"}B). Compared with untreated control cultures, TH^+^ cells in the VC-pretreated cultures exhibited more extensive neurite branching ([Figure S6](#mmc1){ref-type="supplementary-material"}C). Along with an increase in *TH* mRNA expression ([Figure S6](#mmc1){ref-type="supplementary-material"}D), the levels of 5hmC at human *TH* promoter regions (two consensus NURR1 binding sites; NGFI-B response element) were enhanced at the expense of 5mC levels by VC pretreatment, but H3K9m3/H3K27m3 levels, which significantly decreased in the rat *Th* promoter after VC pretreatment, were undetectable in the human *TH* promoter regions ([Figure S6](#mmc1){ref-type="supplementary-material"}E), indicating similarity and dissimilarity between rodent and human *TH* promoters in VC-mediated epigenetic control. We could not assess VC effects on midbrain-specific gene expressions in human NSCs, since the hESC-derived NSCs partially adopt VM phenotypes ([@bib21]), and authentic human VM-NSC cultures are currently not available. Although further assessments are required in authentic human VM-NSC cultures when they are available, the observed benefits of VC pretreatment in human NSC-DA differentiation and differentiated cell survival are at least applicable in PD cell therapeutic approaches. Given the high VC levels in brain cells ([@bib11]), VC treatment is physiologic. VC treatment of donor cells was simple and safe without necessity for VC supplementation into the grafted brain. Therefore, use of this VC pretreatment strategy during preparation of donor NSCs could become a PD cell therapy option in the clinical setting.

Experimental Procedures {#sec4}
=======================

Cell Culture {#sec4.1}
------------

NSCs were cultured from rat embryo VMs (Sprague-Dawley) at E12 or derived by *in vitro* differentiation of hESCs (H9) as previously described ([@bib34]). The methods are described in detail in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Epigenetic Assays {#sec4.2}
-----------------

Determination of TET and JMJD enzyme activities, global 5mC/5hmC and H3K9m3/H3K27m3 levels, ChIP-qPCR and DIP-qPCR analyses were carried out as previously described ([@bib12]) and are described in detail in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

*In Vivo* Animal Experiments {#sec4.3}
----------------------------

All procedures for animal experiments were approved by the Institutional Animal Care and Use Committee at Hanyang College of Medicine (approval number 2014-0212A). Experiments were performed in accordance with NIH guidelines. Hemi-parkinsonism was induced in adult female Sprague-Dawley rats (220--250 g) by unilateral stereotactic injection of 3 μL of 6-OHDA (8 μg/μL; Sigma). Transplantation and histological procedures are described in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Cell Counting and Statistical Analysis {#sec4.4}
--------------------------------------

Immunostained cells were counted in 10--20 random areas of each culture coverslip using an eyepiece grid at a magnification of 200×. All data are expressed as the mean ± SEM of three to eight independent experiments. Statistical comparisons were made using Student\'s t test (unpaired) or one-way ANOVA followed by Tukey\'s post hoc analysis using SPSS Statistics 21 (IBM). The relevant n and p values, and statistical analysis methods are indicated in each figure legend.
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